Investors sold shares of Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) on strength during trading hours on Wednesday. $38.59 million flowed into the stock on the tick-up and $62.69 million flowed out of the stock on the tick-down, for a money net flow of $24.10 million out of the stock. Of all companies tracked, Alexion Pharmaceuticals had the 0th highest net out-flow for the day. Alexion Pharmaceuticals traded up $2.77 for the day and closed at $126.93

Several research firms recently commented on ALXN. Cowen and Company reaffirmed a “buy” rating on shares of Alexion Pharmaceuticals in a report on Sunday, April 17th. Leerink Swann reissued a “buy” rating and issued a $200.00 price target on shares of Alexion Pharmaceuticals in a report on Sunday. Jefferies Group reissued a “hold” rating on shares of Alexion Pharmaceuticals in a report on Sunday, May 29th. Piper Jaffray Cos. reissued a “buy” rating on shares of Alexion Pharmaceuticals in a report on Sunday, June 26th. Finally, Credit Suisse Group AG raised shares of Alexion Pharmaceuticals from a “neutral” rating to an “outperform” rating in a report on Saturday, July 9th. Seven equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and two have given a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $190.61.

The firm’s 50 day moving average price is $128.18 and its 200 day moving average price is $142.35. The company has a market cap of $28.43 billion and a PE ratio of 192.03.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its earnings results on Thursday, April 28th. The biopharmaceutical company reported $1.11 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.13 by $0.02. The company had revenue of $701 million for the quarter, compared to analysts’ expectations of $710.98 million. During the same period last year, the company posted $1.28 EPS. The business’s revenue was up 16.8% compared to the same quarter last year. On average, equities research analysts forecast that Alexion Pharmaceuticals Inc. will post $5.05 earnings per share for the current fiscal year.

In related news, EVP Martin Mackay sold 4,097 shares of the company’s stock in a transaction on Monday, May 16th. The shares were sold at an average price of $139.20, for a total transaction of $570,302.40. Following the completion of the transaction, the executive vice president now owns 42,706 shares in the company, valued at $5,944,675.20. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP John B. Moriarty sold 918 shares of the company’s stock in a transaction on Monday, June 13th. The stock was sold at an average price of $135.72, for a total transaction of $124,590.96. Following the transaction, the executive vice president now owns 51,360 shares of the company’s stock, valued at approximately $6,970,579.20. The disclosure for this sale can be found here.

Other institutional investors have added to or reduced their stakes in the company. LS Investment Advisors LLC raised its position in Alexion Pharmaceuticals by 1.7% in the fourth quarter. LS Investment Advisors LLC now owns 5,257 shares of the biopharmaceutical company’s stock valued at $1,003,000 after buying an additional 89 shares during the period. Sawtooth Asset Management Inc. raised its position in Alexion Pharmaceuticals by 15,072.9% in the fourth quarter. Sawtooth Asset Management Inc. now owns 7,283 shares of the biopharmaceutical company’s stock valued at $1,389,000 after buying an additional 7,235 shares during the period. Robeco Institutional Asset Management B.V. raised its position in Alexion Pharmaceuticals by 18.9% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 9,909 shares of the biopharmaceutical company’s stock valued at $1,890,000 after buying an additional 1,574 shares during the period. Liberty Mutual Group Asset Management Inc. raised its position in Alexion Pharmaceuticals by 3.1% in the fourth quarter. Liberty Mutual Group Asset Management Inc. now owns 13,522 shares of the biopharmaceutical company’s stock valued at $2,579,000 after buying an additional 409 shares during the period. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its position in Alexion Pharmaceuticals by 1.3% in the fourth quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 14,722 shares of the biopharmaceutical company’s stock valued at $2,808,000 after buying an additional 192 shares during the period.

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.